Imatinib Mesylate from Canada
Imatinib mesylate is a tyrosine kinase inhibitor used primarily as an anticancer drug for treating chronic myeloid leukemia. This aromatic heterocyclic compound with nitrogen hetero-atoms falls under HTS 2933.99.75.00 as it is classified as a drug containing a modified aromatic nitrogen heterocyclic structure.
Duty Rate — Canada → United States
16.5%
Rate breakdown
9903.05.2910%Section 301 (forced labor) — additional 10% ad valorem on products of Canada
Import Tips
• Obtain FDA approval and Drug Master File (DMF) prior to import as it's a pharmaceutical substance
• Ensure Certificate of Analysis (CoA) verifies purity >99% and compliance with USP standards
• Avoid misclassification as a research chemical; declare as bulk drug substance for medicinal use